BR112023021066A2 - Forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composição - Google Patents
Forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composiçãoInfo
- Publication number
- BR112023021066A2 BR112023021066A2 BR112023021066A BR112023021066A BR112023021066A2 BR 112023021066 A2 BR112023021066 A2 BR 112023021066A2 BR 112023021066 A BR112023021066 A BR 112023021066A BR 112023021066 A BR112023021066 A BR 112023021066A BR 112023021066 A2 BR112023021066 A2 BR 112023021066A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- composition
- compound
- chemical formula
- crystalline
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- -1 AND Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000126 substance Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composição. a presente invenção se refere a uma forma cristalina a de um composto de fórmula química 1, a forma cristalina a tendo excelentes propriedades físicas e químicas em comparação com uma forma amorfa e outras formas cristalinas do composto de fórmula química 1. em comparação com a forma amorfa ou outras formas cristalinas, a forma cristalina a do composto de fórmula química 1, de acordo com a presente invenção, não é desnaturada mesmo em condições adversas por um longo período de tempo, possui baixa higroscopicidade, não se altera mesmo sob pressão ou mesmo quando pulverizada, sendo assim adequada para formulação, e também possui estabilidade muito alta, sendo útil para armazenamento a longo prazo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210047169 | 2021-04-12 | ||
| PCT/KR2022/005212 WO2022220519A1 (ko) | 2021-04-12 | 2022-04-11 | 5-[(1,1-디옥시도-4-티오몰포리닐)메틸]-2-페닐-n-(테트라하이드로-2h-피란-4-일)-1h-인돌-7-아민의 신규 결정형 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021066A2 true BR112023021066A2 (pt) | 2023-12-12 |
Family
ID=83640466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021066A BR112023021066A2 (pt) | 2021-04-12 | 2022-04-11 | Forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composição |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240043409A1 (pt) |
| EP (1) | EP4324830A1 (pt) |
| JP (1) | JP2024515630A (pt) |
| KR (1) | KR20220141251A (pt) |
| CN (1) | CN117136185A (pt) |
| BR (1) | BR112023021066A2 (pt) |
| WO (1) | WO2022220519A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023182840A1 (ko) * | 2022-03-25 | 2023-09-28 | 주식회사 미토이뮨테라퓨틱스 | 항바이러스용 약학적 조성물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2178870T3 (en) | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| CN101952281B (zh) | 2008-01-04 | 2014-04-02 | 株式会社Lg生命科学 | 具有细胞、组织及器官保存效果的吲哚及吲唑衍生物 |
| TWI535440B (zh) | 2009-10-26 | 2016-06-01 | Ｌｇ生命科學有限公司 | 包括吲哚化合物之醫藥組成物 |
| CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药（上海）有限公司 | 一种化合物及其晶体 |
| KR101941004B1 (ko) | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
| KR101636563B1 (ko) | 2014-01-24 | 2016-07-06 | 주식회사 엘지생명과학 | 급성 폐 손상 및 급성 호흡곤란 증후군의 예방 또는 치료용 조성물 |
| CN106659722A (zh) | 2014-04-18 | 2017-05-10 | 株式会社Lg生命科学 | 用于预防或治疗脂肪肝疾病的组合物 |
| WO2016072692A2 (ko) | 2014-11-03 | 2016-05-12 | 가톨릭대학교 산학협력단 | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 |
| TW201707707A (zh) * | 2015-03-26 | 2017-03-01 | Ｌｇ生命科學股份有限公司 | 包含吲哚化合物之製劑及其製備方法 |
| KR101852304B1 (ko) | 2016-08-18 | 2018-04-25 | 서울대학교병원 | NecroX를 이용한 줄기세포 유래 심근세포의 분화 효율 및 성숙도 증진 방법 |
-
2022
- 2022-04-11 JP JP2023562931A patent/JP2024515630A/ja active Pending
- 2022-04-11 KR KR1020220044653A patent/KR20220141251A/ko unknown
- 2022-04-11 WO PCT/KR2022/005212 patent/WO2022220519A1/ko active Application Filing
- 2022-04-11 BR BR112023021066A patent/BR112023021066A2/pt unknown
- 2022-04-11 US US18/000,712 patent/US20240043409A1/en active Pending
- 2022-04-11 CN CN202280028250.9A patent/CN117136185A/zh active Pending
- 2022-04-11 EP EP22788375.8A patent/EP4324830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117136185A (zh) | 2023-11-28 |
| US20240043409A1 (en) | 2024-02-08 |
| WO2022220519A1 (ko) | 2022-10-20 |
| KR20220141251A (ko) | 2022-10-19 |
| EP4324830A1 (en) | 2024-02-21 |
| JP2024515630A (ja) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021066A2 (pt) | Forma cristalina a, método para preparar a forma cristalina a, composição farmacêutica, e, composição | |
| US11059926B2 (en) | Acryloyl-based copolymers, terpolymers, and use as hydrate inhibitors | |
| TW200702339A (en) | Propylene polymer with high crystallinity and its process and goods | |
| WO2021050223A8 (en) | Polymer composition for laser direct structuring | |
| WO2009028646A1 (ja) | 架橋剤、架橋高分子、およびそれらの用途 | |
| BR112017028075A2 (pt) | material de base sólida para uso externo na pele, composição aquosa e método de para sua produção | |
| GR1000851B (el) | Συνθεσεις γραμμικου ιξωδοελαστικου υδατικου υγρου απορρυπαντικου ειδικα για αυτοματα πλυντηρια πιατων η βελτιωμενη σταθεροτητα σε υψηλη θερμοκρασια. | |
| WO2009067166A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| BR112023024881A2 (pt) | Composição contendo metacrilato de metila, método de armazenagem para composição contendo metacrilato de metila e método de produção para polímero de metacrilato de metila | |
| BR112018010985A2 (pt) | espuma expansível em calor para cura de baixa temperatura | |
| BR0212716A (pt) | Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica | |
| CO2024000054A2 (es) | Forma cristalina de tolebrutinib y método de preparación y su uso | |
| BR112022007604A2 (pt) | Composto de 3-n-ciclopropilmetil-2-fluorobenzamida. composto, e, uso do composto 3-n-ciclopropilmetil-2-fluorobenzamida | |
| BR112023022409A2 (pt) | Composição contendo metacrilato de metila e método de produção de polímero de metacrilato de metila | |
| CO2021015974A2 (es) | Composiciones a base de polietileno y películas y artículos que las comprenden | |
| KR20080092165A (ko) | 백색 분말상 수성 이형제 조성물 | |
| TW200718673A (en) | Process for producing aromatic sulfonic acid compound | |
| MX2022013528A (es) | Procesos para la preparacion de un inhibidor de cinasa. | |
| CL2023001221A1 (es) | Agonista del receptor de melanocortina-4 amorfo | |
| TW200643074A (en) | Method for producing extruded foam of polyhydroxyalkanoate resin and extruded foam produced by the production method | |
| GB769372A (en) | Lubricating oil compositions | |
| TWI748963B (zh) | 乳膏型清潔組成物及其製造方法 | |
| US3956001A (en) | Retarding skin formation on asphalt in hot storage | |
| JP2005120172A (ja) | 潤滑剤組成物 | |
| JPH07508547A (ja) | 潤滑剤および離型剤における１，３−ジオキサンの使用 |